Sahil Khanna MBBS, Darrell S. Pardi MD, Dale N. Gerding MD, Ken Blount PhD, Courtney Jones, Bill Shannon PhD MBA, Elena Deych MS Background Microbiota-based therapies are demonstrating efficacy in preventing recurrent Clostridium difficile infections (rCDI). RBX7455 is a first-of-its-kind, lyophilized, non-frozen, orallyadministered microbiota-restoring drug candidate that was developed for ease-of-use for rCDI patients. Herein we present clinical […]
Microbiota Restoration Therapy Posters
Evaluating a Prototype MICROBIOME HEALTH INDEX™ (MHI™) as a Measure of Microbiome Restoration Using Data Derived From Published Studies of Fecal Microbiota Transplant to Treat recurrent Clostridium difficile Infections (rCDI)
Ken Blount PhD, Courtney Jones BS, Elena Deych MS, Bill Shannon PhD MBA Background There are efforts to develop FDA-approved microbiotabased drugs to restore the microbiome, notably for recurrent Clostridium difficile infections (rCDI). Given the lack of established biomarkers for microbiome restoration, we are evaluating unidimensional microbiome-based indices, such as the MICROBIOME HEALTH INDEX™ (MHI™), […]
Prevention of Recurrent Clostridium difficile at Six Months Following Treatment with Microbiota-based Therapy RBX2660: Durability Results From a Phase 2 Open-label Study
Sarah Mische PhD, Robert Orenstein DO, Erik R. Dubberke MD, Sahil Khanna MBBS, Gail Hecht MD, Herbert Dupont MD, Christine H. Lee MD, Dale N. Gerding MD, Ken Blount PhD Background Effective treatment options for recurrent C. difficile infection (rCDI) are limited. High recurrence rates are associated with current standard-of-care antibiotic therapy. Microbiota-based therapies are being […]
A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455
Ken Blount PhD, Courtney Jones BS, Sahil Khanna MBBS, Elena Deych MS, Bill Shannon PhD MBA Background Recurrent Clostridium difficile infections (rCDI) are strongly associated with dysbiosis—disruption of a healthy intestinal microbiome We have developed two forms of Microbiota Restoration Therapy™: RBX7455 is a first-of-its-kind room temperature stable, orally administered MRT; and RBX2660, a ready […]
A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome
Sahil Khanna MBBS, Darrell S. Pardi MD, Dale N. Gerding MD, Ken Blount PhD, Courtney Jones, Bill Shannon PhD MBA, Elena Deych MS Background Microbiota-based therapies are demonstrating efficacy in preventing recurrent Clostridium difficile infections (rCDI). RBX7455 is a first-of-its-kind, lyophilized, non-frozen, orally-administered microbiota-restoring drug candidate that was developed for ease-of-use for rCDI patients. Herein […]